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omparability of Noninvasive
icrovolt T-Wave Alternans
ersus Invasive Ventricular
rogrammed Stimulation
o Guide Implantable
ardioverter-Defibrillator
mplantation in Patients at
isk of Sudden Death*
regory K. Feld, MD, FACC, FHRS,†
aul Clopton, MS‡
an Diego, California
n this issue of the Journal, Costantini et al. (1) publish a
tudy comparing noninvasive microvolt T-wave alternans
MTWA) with invasive electrophysiological study with
entricular programmed stimulation (EPS) to identify pa-
ients at risk of sudden cardiac death (SCD) who might
enefit from an implantable cardioverter-defibrillator
ICD).
See page 471
The authors (1) noted that primary prevention trials, for
xample MADIT-I (Multicenter Automatic Defibrillator
rial) and MUSTT (Multicenter Unsustained Tachycardia
rial) (2,3), used EPS to identify high risk of SCD in
atients with prior myocardial infarction, reduced left ven-
ricular ejection fraction (LVEF) of 0.35 to 0.40, sponta-
eous nonsustained ventricular tachycardia (NSVT), and
nducible sustained ventricular tachycardia (VT) at EPS
which was not suppressed by antiarrhythmic drugs in
ADIT-I). This rigorous invasive approach identified
atients in whom overall mortality was significantly reduced
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Medicine, Division of Cardiology, University of
alifornia, San Diego, California; and the ‡Veterans Affairs San Diego Healthcare
ystem, San Diego, California. Dr. Feld is a consultant to Medwaves, Inc. and Sequelw
harmaceutical Inc., and receives research and fellowship program support from
oston Scientific, Inc., Medtronic Inc., Biotronic, and St. Jude Inc.y ICD implantation compared with conventional antiar-
hythmic drug therapy during maximum follow-up of 5
ears. Of note, overall mortality was also high (44%) in the
USTT registry in patients who had no inducible VT at
PS (4). Thus, in patients with myocardial infarction and
educed LVEF, the risk of mortality is high regardless of
nducibility of VT at EPS, although EPS might identify
atients at highest risk who are more likely to benefit from
CD implantation.
In the subsequent MADIT-II trial (5), designed to
liminate the need for EPS, patients with myocardial
nfarction and LVEF 0.30 were randomized to ICD
mplantation versus conventional medical therapy only.
CD implantation produced a smaller yet significant reduc-
ion in overall mortality versus conventional medical therapy
14.2% vs. 19.8%) during a maximum follow-up of 53
onths.
Among alternative noninvasive screening tools, MTWA
as been shown to be useful for risk stratification for
rimary prevention of SCD (6–9). However, its high
egative predictive value (NPV) might be its most valuable
sset (6–9). Therefore, Costantini et al. (1) designed the
BCD trial to test the hypothesis that, in patients with
oronary artery disease and reduced LVEF, MTWA would
erform at least as well as EPS to identify increased risk for
CD. In addition, the authors hypothesized that MTWA,
ither alone or in combination with EPS, would identify
atients more likely to benefit from ICD implantation
ompared with stratification by LVEF alone.
Costantini et al. (1) partly justify their study by noting
hat 4 ICDs must be implanted to save 1 life with
ADIT-I and MUSTT criteria and 15 to 17 ICDs must
e implanted to save 1 life with MADIT-II criteria (2–5).
oreover, many ICD patients never receive therapy. None-
heless, current guidelines reflect MADIT-II findings (5),
ecommending ICD implantation for primary prevention of
CD in patients with an LVEF 0.35 without requiring
PS to guide therapy. The authors (1) hoped that use of
TWA might reduce this ratio of ICD implants to life
aved and avoid invasive EPS.
In the ABCD trial, Costantini et al. (1) enrolled patients
ith NSVT and LVEF 0.40 attributable to ischemic
eart disease. The trial was designed to compare an
TWA-guided with EPS-guided strategy in predicting
rrhythmic events. The MTWA strategy was defined as
ositive (high risk) if MTWA was abnormal or if MTWA
as indeterminate and EPS was abnormal, whereas the
TWA strategy was defined as negative (low risk) if
TWA was normal or if MTWA was indeterminate and
PS was normal. Thus, all patients with reduced LVEF
ould be screened noninvasively with MTWA and undergo
PS only if MTWA was indeterminate. However, because
n overlap would then exist between the MTWA and EPS
roups, pre-specified secondary analyses were performed
ith a standard definition of MTWA positivity that ex-
c
v
i
n
n
i
I
4
4
o
y
o
S
M
(
M
r
i
p
M
n
2
p
l
M
c
p
r
c
s
t
(
(
n
w
i
b
t
s
o
a
a
n
d
M
a
w
c
p
i
i
t
t
s
t
i
r
w
s
m
p
p
a
v
n
c
E
m
a
o
M
y
b
c
M
p
s
S
n
r
s
h
c
S
t
s
p
n
b
i
t
R
4
g
R
481JACC Vol. 53, No. 6, 2009 Feld and Clopton
February 10, 2009:480–2 Patients at Risk of Sudden Deathludes patients with indeterminate results and an alternative
alidated method (9) defining patients with positive or
ndeterminate MTWA as abnormal and patients with
egative MTWA as normal. The goal was to demonstrate
oninferiority of MTWA compared with EPS in identify-
ng patients at high risk of SCD who would benefit from
CD implantation.
Costantini et al. (1) followed 566 patients up to 2 years,
6% with positive and 25% with indeterminate MTWA and
0% with positive EPS. The ICDs were inserted in 87%
verall and in 97% with positive MTWA and EPS. One-
ear and 2-year event rates of 7.5% and 14%, respectively,
ccurred in 65 patients, including 55 ICD therapies and 10
CDs. The authors observed a 1.6% difference (9.5% for
TWA vs. 11.1% for EPS) in positive predictive value
PPV) and a 0.2% difference (95.1% for EPS vs. 95.3% for
TWA) in NPV between MTWA and EPS at 1 year,
eportedly falling within their 10% definition of non-
nferiority. In addition, pre-specified analyses comparing
ositive/negative MTWA with EPS and abnormal/normal
TWA with EPS also fell within their 10% definition of
on-inferiority. Interestingly, the event rate in patients with
normal tests was approximately 3-fold lower than in
atients with 1 abnormal test and approximately 6-fold
ower than in patients with 2 abnormal tests, suggesting that
TWA and EPS were complementary in predicting out-
omes. The data also showed that EPS was a significant
redictor of events starting at 9 months and for the
emainder of the study, whereas MTWA was predictive of
linical outcomes at 6 months but not after 12 months.
From a statistical perspective, this noninferiority analysis
hould be understood for what it actually shows. Concep-
ually, non-inferiority tests are designed to show that 1
usually new) method is not a lot worse than another
usually established) method. The key is in setting the
oninferiority margin to prospectively define what “not a lot
orse” actually means. For example, if an existing treatment
s 80% effective and a noninferiority margin of 10% had
een pre-specified, then a significant result would show that
he new treatment is better than 70% effective. Thus, the
trength of the reasonable equivalence claim depends largely
n the size of the pre-specified noninferiority margin.
Because, in the Costantini et al. (1) study, EPS achieved
PPV of 11.1%, the MWTA test would only need to
chieve a PPV significantly better than 1.1% to demonstrate
on-inferiority with a pre-specified margin of 10%. Thus,
emonstrating that the difference in PPV for EPS versus
TWA is 10% is not sufficient to show that the methods
re reasonably equivalent. In contrast, if a smaller margin
as used, such as 2% instead of 10%, it is unlikely that the
urrent sample size would be sufficient to provide adequate
ower to test the noninferiority hypothesis. The non-
nferiority test for NPV is also plagued by the wide margin
ssue, although to a lesser degree.
Therefore, the Costantini et al. (1) data should not be
aken as evidence that MTWA can replace EPS or as proofhat the 2 are reasonably equivalent. What then does the
tudy tell us? The current data are best taken as suggesting
hat MTWA should be studied further to determine its role
n identification of patients with ischemic heart disease and
educed LVEF who are at highest risk for SCD and in
hom ICD implantation might be warranted. The data also
how that the event rates are low and the PPV of both
ethods is low. Thus, if either method is used to guide
ractice, the number of ICDs inserted that actually benefit
atients is expected to remain low.
From a clinical perspective, the Costantini et al. study (1)
lso has several limitations. This study (1) demonstrated a
ery low event rate at 1 year (i.e., strong NPV) in the
egative MTWA (95.3%) and EPS (95.2%) patients, which
ontrasts with the relatively high event rate (44%) in the
PS negative patients in the MUSTT registry (4). This
ight actually favor use of negative MTWA and EPS,
lone or in combination, for stratification of patients at risk
f SCD who won’t benefit from ICD therapy. However, the
USTT study (4) spanned a much longer time frame of 5
ears, which might negate the NPV of MTWA suggested
y this shorter-term (1.6  0.6 year) study (1). It is also
oncerning that this study (1) showed a loss of PPV of
TWA after 12 months, compared with EPS, which
redicted events after 9 months for the duration of the
tudy, suggesting a possible difference in mechanism of
CD predicted by these 2 tests. Finally, this study (1) did
ot evaluate patients with nonischemic cardiomyopathy at
isk of SCD, in whom ICD implantation has also been
hown to significantly reduce overall mortality (10,11).
Thus, although the Costantini et al. (1) study might not
ave shown comparability or noninferiority of MTWA
ompared with EPS in identification of patients at risk of
CD who would benefit from ICD implantation, it cer-
ainly can be used as an example for the design of future
imilar studies. However, such a study should either incor-
orate a narrower margin of noninferiority or enroll a larger
umber of patients to ensure adequate power. It might also
e appropriate in such a study to enroll patients with both
schemic and nonischemic cardiomyopathy and to follow
hem over a longer period of time.
eprint requests and correspondence: Dr. Gregory K. Feld,
168 Front Street, San Diego, California 92103-8649. E-mail:
feld@ucsd.edu.
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